1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Int'l Group Co., Ltd. Class A

Zhejiang Int'l Group Co., Ltd. Class A

SSZSE:000411
9.56
CNY
+0.11
(+1.16%)
1.13EPS
11.35P/E
6.13BMarket Cap
Zhejiang Int'l Group Co., Ltd. Class A
SZSE:000411
(Shenzhen Stock Exchange)

Recent

price

9.56

P/E

ratio

11.35

div

yld

6.52%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
26.09
34.15
43.03
50.08
57.34
61.86
69.55
75.49
81.88
89.55
83.76
89.2
102.35
71.48
64.73
64.5
63.96
Revenue per Share
0.17
0.75
0.28
0.3
0.27
0.27
0.35
0.33
0.37
0.55
0.53
0.56
0.71
1.09
1.02
0.96
0.96
Basic EPS, GAAP
0.16
-0.58
-0.08
0.06
0.05
-0.25
0.19
0.27
0.21
0.3
0.51
0.46
0.95
0.57
0.25
0.23
- -
Free Cash Flow per Basic Share
0.14
0.3
0.37
0.4
0.49
0.41
0.37
0.52
0.52
0.72
0.41
0.52
0.61
0.47
0.57
0.63
0.62
Dividend per Share
0.88
1.62
1.88
2.18
2.44
2.71
3.05
3.39
3.74
5.08
5.56
6.19
6.72
8.14
8.88
9.44
9.57
Book Value per Share
0.76
1.36
1.44
1.74
1.96
2.23
2.57
2.46
2.87
4.27
4.78
5.3
5.84
7.49
7.96
8.15
8.34
Tangible Book Value per Share
254
250
246
247
245
250
248
250
250
275
299
300
299
448
515
522
531
Basic Weighted Avg Shares
6,638
8,526
10,590
12,369
14,074
15,466
17,257
18,907
20,492
24,601
25,008
26,731
30,619
32,052
33,352
33,679
33,940
Sales/Revenue/Turnover
2.45
2.32
2.72
2.37
2.12
2.12
2.21
2.19
2.36
2.42
2.38
2.58
2.63
2.81
2.88
2.97
2.85
Operating Margin (%)
12
16
25
26
32
35
37
49
58
79
76
135
146
164
191
208
- -
Depreciation Expense
42
187
68
74
65
69
87
83
94
151
157
168
212
489
526
501
507
Net Income, GAAP
27.36
26.65
27.94
29.04
32.31
28.35
27.8
30.59
26.98
27.56
26.49
26.73
26.07
26.54
23.78
26.04
23.41
Effective Tax Rate (%)
0.64
2.2
0.64
0.6
0.47
0.44
0.5
0.44
0.46
0.61
0.63
0.63
0.69
1.52
1.58
1.49
1.5
Profit Margin (%)
133
525
600
808
875
908
1,035
1,121
1,635
2,080
2,515
3,015
3,037
3,806
3,922
3,832
3,890
Working Capital
- -
- -
- -
33
16
8
25
85
414
250
627
879
548
672
583
385
166
LT Debt
458
917
1,048
1,245
1,367
1,516
1,697
1,905
2,083
2,972
3,206
3,516
3,877
4,781
5,210
5,781
6,104
Total Equity
8.89
29.7
8.65
8.75
5.48
6.06
7.11
5.55
5.12
6.91
6.05
6.59
7.73
9.1
8.41
7.4
6.91
Return on Invested Capital (%)
3.54
3.63
4.01
2.74
3.79
2.78
2.46
2.08
1.81
1.84
1.31
0.93
1.33
7.77
7.43
6.17
5.73
Return on Capital (%)
21.7
60.01
15.52
14.67
11.38
10.72
12.12
10.42
10.58
12.35
9.87
9.44
10.68
15.43
11.82
10.29
10.11
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
3,466
3,024
4,214
LT Borrowings
401
239
36
LT Finance Leases
133
146
130
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
522
541
565
Market Capitalization
5,595
6,895
6,129

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
14,361
14,338
15,035
Cash, Cash Equivalents & STI
1,795
1,942
1,678
Accounts Receivable, Net
7,350
7,310
7,973
Inventories
3,974
4,290
4,422
Total Current Liabilities
10,473
10,506
11,145
Payables & Accruals
- -
- -
- -
ST Debt
3,466
3,024
4,214
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.73%
12.64%
10.97%
Free Cash Flow
1.47%
5.7%
-9.12%
Net Income, GAAP
26.62%
33.33%
-4.62%
Sales/Revenue/Turnover
8.24%
6.23%
0.98%
Total Cash Common Dividend
15.71%
22.3%
11.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,598
8,013
8,166
8,575
33,352
2025
8,437
8,192
- -
8,717
33,679
2026
8,595
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.29
0.19
0.33
1.02
2025
0.19
0.28
- -
0.34
0.96
2026
0.14
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.37
0.06
0.08
0.57
2025
0.06
0.44
- -
0.08
0.63
2026
0.05
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang Int'l Group Co., Ltd. is a China-based company principally engaged in the wholesale and retail of pharmaceuticals and medical devices. The company’s main products include chemical drugs, biological products, traditional Chinese medicines, Chinese patent drugs, pharmaceutical apparatus, and healthcare products. It operates through several business centers including pharmaceutical distribution, traditional Chinese medicine industry, biotechnology and medical device expansion, strategic support, and marketing networks. Zhejiang Int'l Group also provides modern logistics and e-commerce services to support its pharmaceutical supply chain. The company was founded in 1950 and is headquartered in Hangzhou, China. It is a state-owned enterprise controlled by Zhejiang Pharmaceutical and Health Industry Group Holdings, and was formerly part of Sinochem Group. Zhejiang Int'l Group has undergone significant asset restructuring and business realignment over recent years, focusing its core operations on pharmaceuticals, traditional Chinese medicine, biological products, and medical equipment distribution. It has more than ten subsidiaries and holds a prominent regional position in pharmaceutical distribution and retail. Recent major changes include completing the acquisition of the remaining 50% stake in Zhejiang Int'l Medicine Co., Ltd., enhancing its operational control and integration. The company has emphasized strategic expansion in logistics and e-commerce as part of its business transformation within the last two years. It upholds a mission to become the top professional pharmaceutical supply chain comprehensive service provider in China, strengthening its service offerings and network capabilities. Zhejiang Int'l Group has consistently been recognized for internal control and supply chain innovation at the provincial level. The company’s target markets primarily encompass domestic China with progressive international outreach through its pharmaceutical and medical product lines. It maintains strong industry credentials and partnerships that support its sustained growth and modernization efforts, including digital transformation initiatives and research and development investment to innovate in biotechnology and healthcare products. Overall, Zhejiang Int'l Group Co., Ltd. combines pharmaceutical manufacturing, wholesale, retail, and supply chain services with strategic investments in logistics and e-commerce, positioning it as a key player in China's pharmaceutical industry landscape with expanding operational capabilities and recent corporate restructuring achievements.